Clinical Implications of the Relationship Between Naltrexone Plasma Levels and the Subjective Effects of Heroin in Humans.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
21 Dec 2023
21 Dec 2023
Historique:
medline:
21
12
2023
pubmed:
21
12
2023
entrez:
21
12
2023
Statut:
aheadofprint
Résumé
Extended-release naltrexone (NTX) is an opioid antagonist approved for relapse prevention after medical withdrawal. Its therapeutic effect is dependent on the NTX plasma level, and as it decreases, patients may lack protection against relapse and overdose. Therefore, identifying the minimally effective NTX level needed to block opioid-induced subjective effects has important clinical implications. This secondary, individual-level analysis of data collected in a human laboratory study was conducted to evaluate the relationship between NTX levels and subjective effects of an intravenously administered 25-mg challenge dose of heroin in non-treatment-seeking participants with opioid use disorder (N = 12). Subjective ratings of drug liking using a 100-mm visual analog scale (VAS) and NTX levels were measured across 6 weeks after participants received a single injection of either extended-release NTX 192 mg (N = 6) or 384 mg (N = 6). Cubic spline mixed-effects models were used to provide 95% prediction intervals for individual changes in liking scores as a function of NTX levels. Naltrexone levels above 2 ng/mL blocked nearly all VAS ratings of drug liking after intravenous heroin administration. Participants with NTX levels ≥ 2 ng/mL had minimal (≤20 mm) changes from placebo in VAS ratings of drug liking based on 95% prediction intervals. In contrast, NTX levels < 2 ng/mL were associated with greater variability in individual-level subjective responses. In clinical practice, a plasma level range of 1 to 2 ng/mL is considered to be therapeutic in providing heroin blockade. The current findings suggest that a higher level (>2 ng/mL) may be needed to produce a consistent blockade.
Sections du résumé
BACKGROUND
BACKGROUND
Extended-release naltrexone (NTX) is an opioid antagonist approved for relapse prevention after medical withdrawal. Its therapeutic effect is dependent on the NTX plasma level, and as it decreases, patients may lack protection against relapse and overdose. Therefore, identifying the minimally effective NTX level needed to block opioid-induced subjective effects has important clinical implications.
METHODS
METHODS
This secondary, individual-level analysis of data collected in a human laboratory study was conducted to evaluate the relationship between NTX levels and subjective effects of an intravenously administered 25-mg challenge dose of heroin in non-treatment-seeking participants with opioid use disorder (N = 12). Subjective ratings of drug liking using a 100-mm visual analog scale (VAS) and NTX levels were measured across 6 weeks after participants received a single injection of either extended-release NTX 192 mg (N = 6) or 384 mg (N = 6). Cubic spline mixed-effects models were used to provide 95% prediction intervals for individual changes in liking scores as a function of NTX levels.
RESULTS
RESULTS
Naltrexone levels above 2 ng/mL blocked nearly all VAS ratings of drug liking after intravenous heroin administration. Participants with NTX levels ≥ 2 ng/mL had minimal (≤20 mm) changes from placebo in VAS ratings of drug liking based on 95% prediction intervals. In contrast, NTX levels < 2 ng/mL were associated with greater variability in individual-level subjective responses.
CONCLUSIONS
CONCLUSIONS
In clinical practice, a plasma level range of 1 to 2 ng/mL is considered to be therapeutic in providing heroin blockade. The current findings suggest that a higher level (>2 ng/mL) may be needed to produce a consistent blockade.
Identifiants
pubmed: 38126709
doi: 10.1097/ADM.0000000000001247
pii: 01271255-990000000-00260
doi:
Banques de données
ClinicalTrials.gov
['NCT03205423']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Society of Addiction Medicine.
Références
Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999-2019. NCHS Data Brief. 2020;394:1–8.
Peterson C, Li M, Xu L, et al. Assessment of annual cost of substance use disorder in US hospitals. JAMA Netw Open. 2021;4(3):e210242.
Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–1513.
Jones CM, Byrd DJ, Clarke TJ, et al. Characteristics and current clinical practices of opioid treatment programs in the United States. Drug Alcohol Depend. 2019;205:107616.
Shulman M, Choo TH, Scodes J, et al. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure. J Subst Abuse Treat. 2021;124:108292.
Alanis-Hirsch K, Croff R, Ford JH, et al. Extended-release naltrexone: A qualitative analysis of barriers to routine use. J Subst Abuse Treat. 2016;62:68–73.
Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210–218.
Jarvis BP, Holtyn AF, Subramaniam S, et al. Extended-release injectable naltrexone for opioid use disorder: A systematic review: Review of XR-NTX for OUD. Addiction. 2018;113(7):1188–1209.
Porter SJ, Somogyi AA, White JM. In vivo and in vitro potency studies of 6ß-naltrexol, the major human metabolite of naltrexone. Addict Biol. 2002;7(2):219–225.
Johnson BA, Ait-Daoud N, Aubin HJ, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res. 2004;28(9):1356–1361.
Dunbar JL, Turncliff RZ, Dong Q, et al. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006;30(3):480–490.
Hamilton RJ. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad Emerg Med. 2002;9(1):63–68.
Hulse GK, Ngo HTT, Tait RJ. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone. Biol Psychiatry. 2010;68(3):296–302.
Kunøe N, Lobmaier P, Vederhus JK, et al. Challenges to antagonist blockade during sustained-release naltrexone treatment: Challenging naltrexone blockade. Addiction. 2010;105(9):1633–1639.
Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: Antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology (Berl). 2006;189(1):37–46.
Lobmaier P, Kornor H, Kunoe N, et al. Sustained-Release Naltrexone For Opioid Dependence. Cochrane Database Syst Rev. 2008;2:CD006140.
Hartung DM, McCarty D, Fu R, et al. Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies. J Subst Abuse Treat. 2014;47(2):113–121.
Blanco C, Volkow ND. Management of opioid use disorder in the USA: Present status and future directions. Lancet. 2019;393(10182):1760–1772.
Trøstheim M, Eikemo M, Haaker J, et al. Opioid antagonism in humans: A primer on optimal dose and timing for central mu-opioid receptor blockade. Neuropsychopharmacology. 2023;48(2):299–307.
Weerts EM, Kim YK, Wand GS, et al. Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacol. 2008;33(3):653–665.
Bigelow GE, Preston KL, Schmittner J, et al. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: Dose-effects and time-course. Drug Alcohol Depend. 2012;123(1–3):57–65.
Comer S, Collins E, Kleber H, et al. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl). 2002;159(4):351–360.
Wright M, De Aquino JP, Bystrak T. Case report: Increasing the frequency of intramuscular naltrexone administration in a high risk patient with opioid use disorder. Subst Abuse. 2021;42(4):493–496.
Wang RIH, Wiesen RL, Lamid S, Roh BL. Rating the presence and severity of opiate dependence. Clin Pharmacol Ther. 1974;16:653–658.
Foltin RW, Fischman MW. Interaction of buprenorphine with cocaine-morphine combinations. Exp Clin Psychopharmacol. 1995;3:261–269.
Huang W, Moody DE, Foltz RL, Walsh SL. Determination of naltrexone and 6-β-naltrexol in plasma by solid-phase extraction and gas chromatography-negative ion chemical ionization-mass spectrometry. J Anal Toxicol. 1997;21:252–257.
Kümmel A, Bonate PL, Dingemanse J, et al. Confidence and prediction intervals for pharmacometric models. CPT Pharmacomet Syst Pharmacol. 2018;7(6):360–373.
Bates D, Mächler M, Bolker B, et al. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1–48.
Breyer-Pfaff U, Nill K. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J Pharm Pharmacol. 2010;56(12):1601–1606.
Galloway GP, Koch M, Cello R, et al. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: An open-label trial. BMC Psychiatry. 2005;5(1):18.
McCaul ME, Wand GS, Rohde C, et al. Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol Clin Exp Res. 2000;24(9):1385–1391.
Comer SD, Burke TF, Lewis JW, et al. Clocinnamox: A novel, systemically-active, irreversible opioid antagonist. J Pharmacol Exp Ther. 1992;262(3):1051–1056.
Sullivan MA, Bisaga A, Mariani JJ, et al. Naltrexone treatment for opioid dependence: Does its effectiveness depend on testing the blockade? Drug Alcohol Depend. 2013;133(1):80–85.